drug · small molecule
venetoclax
Marketedupdated 4mo agoby $ABBV AbbVie Inc.🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 7- drugVENCLEXTA82 co-mentions · 22 sources
- tagApproval80 co-mentions · 20 sources
- tagSmall Molecule40 co-mentions · 20 sources
- tagOncology2 co-mentions · 2 sources
- tagHematology2 co-mentions · 1 sources
- companyInstitute of Hematology and Blood Diseases Hospital1 co-mentions · 1 sources
- tagAML1 co-mentions · 1 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for chronic lymphocytic leukemia and neoplasm and 38 investigational indications.
targets
Apoptosis regulator Bcl-2
all catalysts(22)
approval · 20
Apr 11, 2016
approval
$ABBV260.21-0.58%
VENCLEXTA (VENETOCLAX) — FDA approval
venetoclax
→
Dec 20, 2017
approval
$ABBV260.21-0.58%
VENCLEXTA (VENETOCLAX) — FDA approval
venetoclax
→
Jun 8, 2018
approval
$ABBV260.21-0.58%
VENCLEXTA (VENETOCLAX) — FDA approval
venetoclax
→
Jun 8, 2018
approval
$ABBV260.21-0.58%
VENCLEXTA (VENETOCLAX) — FDA approval
venetoclax
→
Sep 7, 2018
approval
$ABBV260.21-0.58%
VENCLEXTA (VENETOCLAX) — FDA approval
venetoclax
→
Sep 7, 2018
approval
$ABBV260.21-0.58%
VENCLEXTA (VENETOCLAX) — FDA approval
venetoclax
→
Nov 21, 2018
approval
$ABBV260.21-0.58%
VENCLEXTA (VENETOCLAX) — FDA approval
venetoclax
→
May 15, 2019
approval
$ABBV260.21-0.58%
VENCLEXTA (VENETOCLAX) — FDA approval
venetoclax
→
Jul 25, 2019
approval
$ABBV260.21-0.58%
VENCLEXTA (VENETOCLAX) — FDA approval
venetoclax
→
Jul 25, 2019
approval
$ABBV260.21-0.58%
VENCLEXTA (VENETOCLAX) — FDA approval
venetoclax
→
Jul 25, 2019
approval
$ABBV260.21-0.58%
VENCLEXTA (VENETOCLAX) — FDA approval
venetoclax
→
May 29, 2020
approval
$ABBV260.21-0.58%
VENCLEXTA (VENETOCLAX) — FDA approval
venetoclax
→
Jun 12, 2020
approval
$ABBV260.21-0.58%
VENCLEXTA (VENETOCLAX) — FDA approval
venetoclax
→
Oct 16, 2020
approval
$ABBV260.21-0.58%
VENCLEXTA (VENETOCLAX) — FDA approval
venetoclax
→
Oct 16, 2020
approval
$ABBV260.21-0.58%
VENCLEXTA (VENETOCLAX) — FDA approval
venetoclax
→
Nov 19, 2020
approval
$ABBV260.21-0.58%
VENCLEXTA (VENETOCLAX) — FDA approval
venetoclax
→
Oct 4, 2021
approval
$ABBV260.21-0.58%
VENCLEXTA (VENETOCLAX) — FDA approval
venetoclax
→
Oct 22, 2021
approval
$ABBV260.21-0.58%
VENCLEXTA (VENETOCLAX) — FDA approval
venetoclax
→
Jun 15, 2022
approval
$ABBV260.21-0.58%
VENCLEXTA (VENETOCLAX) — FDA approval
venetoclax
→
Feb 19, 2026
approval
$ABBV260.21-0.58%
VENCLEXTA (VENETOCLAX) — FDA approval
venetoclax
→
phase 1 2 completion · 1
Trials studying venetoclax
- phase2Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)
- phase2Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)
- phase2Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
- phase2Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma
- phase1A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
- phase3A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- phase2A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia
- phase3A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Patent cliff
source: FDA Orange Bookfirst barrier falls
May 26, 2030
~3.7 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (30)
- Sep 6, 2033method-of-use (U-3114)US 10993942
- Sep 6, 2033method-of-use (U-3114)US 10993942
- Sep 6, 2033method-of-use (U-3114)US 10993942
- Sep 6, 2033method-of-use (U-3223)US 11110087
- Sep 6, 2033method-of-use (U-3223)US 11110087
- Sep 6, 2033method-of-use (U-3223)US 11110087
- Sep 6, 2033method-of-use (U-3412)US 11413282
- Sep 6, 2033method-of-use (U-3412)US 11413282
- Sep 6, 2033method-of-use (U-3412)US 11413282
- Sep 6, 2033method-of-use (U-3548)US 11590128
- Sep 6, 2033method-of-use (U-3548)US 11590128
- Sep 6, 2033method-of-use (U-3548)US 11590128
- Sep 6, 2033method-of-use (U-2538)US 9539251
- Sep 6, 2033method-of-use (U-2538)US 9539251
- Sep 6, 2033method-of-use (U-2538)US 9539251
- May 23, 2032formulationUS 11369599
- May 23, 2032formulationUS 11369599
- May 23, 2032formulationUS 11369599
- Jan 29, 2032compositionUS 8722657
- Jan 29, 2032compositionUS 8722657
- Jan 29, 2032compositionUS 8722657
- Nov 21, 2031compositionUS 10730873
- Nov 21, 2031compositionUS 10730873
- Nov 21, 2031compositionUS 10730873
- Jun 27, 2031compositionUS 85463994.8y
- Jun 27, 2031compositionUS 85463994.8y
- Jun 27, 2031compositionUS 85463994.8y
- May 26, 2030method-of-use (U-2323)US 91749823.7y
- May 26, 2030method-of-use (U-2446)US 91749823.7y
- May 26, 2030method-of-use (U-2445)US 91749823.7y
FDA exclusivities (3)
- May 15, 2026ODE-239Orphan Drug (7y)
- May 15, 2026ODE-239Orphan Drug (7y)
- May 15, 2026ODE-239Orphan Drug (7y)
News(10)
- Chutes & Ladders—Legend CEO departs without successor in placeLegend Biotech CEO Ying Huang, Ph.D., has left the company suddenly, without a predecessor in place. Huang was elevated from CFO to CEO in 2020 after a Chinese customs investigation was opened on f…fiercebiotech · 1mo ago
- Sarepta names former AbbVie R&D exec Michael Severino as next CEOAfter leaving Tessera Therapeutics earlier this month, Michael Severino will take over Sarepta Therapeutics as the biotech awaits two key regulatory decisions in Duchenne muscular dystrophy.biospace · 1mo ago
- Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workersHundreds of executives and investors are pushing for Rick Pazdur to be the next FDA commissioner. Elsewhere, Takeda detailed its latest restructuring and Alumis is discarding a once-highly touted i…biopharma_dive · 3mo ago
- BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at VenclextaBeOne Medicines has clinched an accelerated approval for its drug sonrotoclax in mantle cell lymphoma (MCL), marking the start of its bid to challenge AbbVie and Roche's Venclexta across a range of…endpoints · 3mo ago
- Dr Loghavi on the Significance of Updated WHO Diagnostic Criteria for AML in Clinical PracticeSanam Loghavi, MD, discusses updated WHO diagnostic criteria for acute myeloid leukemia and its significance for diagnoses and treatment selection.onclive · 3mo ago
- FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AMLThe FDA has approved oral decitabine/cedazuridine plus venetoclax for newly diagnosed AML unfit for intensive chemo, based on phase 2 ASCERTAIN-V data.onclive · 3mo ago
- FDA Approves Sonrotoclax for Relapsed/Refractory Mantle Cell LymphomaThe FDA granted accelerated approval to sonrotoclax for relapsed/refractory mantle cell lymphoma after at least 2 lines of systemic therapy.onclive · 3mo ago
- Dr Dinardo on the FDA Approval of Decitabine/Cedazuridine Plus Venetoclax in AMLCourtney D. DiNardo, MD, MSCE, discusses the FDA approval of decitabine/cedazuridine plus venetoclax in acute myeloid leukemia.onclive · 3mo ago
- Combination and Sequencing Strategies in Metastatic Castration-Resistant Prostate CancerDr. Pedro Barata and Dr. Johann De Bono discuss ongoing questions surrounding combination approaches and optimal sequencing strategies for radiopharmaceutical therapies in metastatic castration-res…onclive · 3mo ago
- Treatment Sequencing in Metastatic Castration-Resistant Prostate CancerDr. Johann De Bono and Dr. Pedro Barata discuss the evolving role of treatment sequencing and patient selection for radiopharmaceuticals in metastatic castration-resistant prostate cancer (mCRPC).onclive · 3mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that